Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy pairs the broad-spectrum antimicrobial and anti-inflammatory properties of tea tree oil with the microbiome-supporting benefits of prebiotics. Tea tree oil, specifically its primary constituent terpinen-4-ol, exerts its effect by disrupting the cell membranes of bacteria, fungi, and mites (such as *Demodex* species), while also reducing the production of inflammatory mediators. The inclusion of prebiotics—typically oligosaccharides such as inulin or alpha-glucan—serves to nourish beneficial skin commensals like *Staphylococcus epidermidis*, thereby promoting a healthy microbial balance and strengthening the skin's natural barrier against pathogens. This synergistic approach is primarily utilized in the management of eyelid hygiene for blepharitis and Demodex infestations, as well as in specialized dermatological and intimate care products to treat or prevent dysbiosis-related conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tea tree oil + prebiotic.